Overview

Safety, Pharmacokinetics, and Efficacy Study of NB-001 to Treat Recurrent Herpes Labialis

Status:
Completed

Trial end date:
2007-12-01

Target enrollment:

Participant gender:

Summary

Purpose of this study is to determine the safety and efficacy of topical applications of NB-001 as compared to placebo for the treatment of recurrent herpes labialis.

Phase:

Phase 2

Details

Lead Sponsor:

NanoBio Corporation

Treatments:

5- ((2- (6- Amino- 9H- purin- 9- yl) ethyl) amino) - 1- pentanol
5-((2-(6-Amino-9H-purin-9-yl) ethyl) amino)-1-pentanol